Pharmacologic advances in the systemic treatment of itch

Brett T. Summey, Gil Yosipovitch

Research output: Contribution to journalReview article

46 Citations (Scopus)

Abstract

Itch is propagated by complex mechanisms located both peripherally and within the central nervous system. For decades, novel treatments of itch have been slow to emerge, with the majority of focus on antagonism of histamine. Recently, with a new understanding of the pathophysiology of itch transmission, new treatment strategies have been elucidated. Opiate receptor antagonists, antidepressants, antiepileptics, and thalidomide are currently available therapeutic options that have benefited many patients with variegated sources of itch. In addition, research focused on the neuromediators of itch transmission has led to the development of novel targets for itch reduction and great potential for future therapies.

Original languageEnglish (US)
Pages (from-to)328-332
Number of pages5
JournalDermatologic Therapy
Volume18
Issue number4
DOIs
StatePublished - Jul 1 2005
Externally publishedYes

Fingerprint

Thalidomide
Opioid Receptors
Therapeutics
Anticonvulsants
Histamine
Antidepressive Agents
Central Nervous System
Research

Keywords

  • Opioid agonists and antagonists
  • SSRIs
  • Thalidomide

ASJC Scopus subject areas

  • Dermatology

Cite this

Pharmacologic advances in the systemic treatment of itch. / Summey, Brett T.; Yosipovitch, Gil.

In: Dermatologic Therapy, Vol. 18, No. 4, 01.07.2005, p. 328-332.

Research output: Contribution to journalReview article

@article{e23754122a184792a45370040219ebac,
title = "Pharmacologic advances in the systemic treatment of itch",
abstract = "Itch is propagated by complex mechanisms located both peripherally and within the central nervous system. For decades, novel treatments of itch have been slow to emerge, with the majority of focus on antagonism of histamine. Recently, with a new understanding of the pathophysiology of itch transmission, new treatment strategies have been elucidated. Opiate receptor antagonists, antidepressants, antiepileptics, and thalidomide are currently available therapeutic options that have benefited many patients with variegated sources of itch. In addition, research focused on the neuromediators of itch transmission has led to the development of novel targets for itch reduction and great potential for future therapies.",
keywords = "Opioid agonists and antagonists, SSRIs, Thalidomide",
author = "Summey, {Brett T.} and Gil Yosipovitch",
year = "2005",
month = "7",
day = "1",
doi = "10.1111/j.1529-8019.2005.00035.x",
language = "English (US)",
volume = "18",
pages = "328--332",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Pharmacologic advances in the systemic treatment of itch

AU - Summey, Brett T.

AU - Yosipovitch, Gil

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Itch is propagated by complex mechanisms located both peripherally and within the central nervous system. For decades, novel treatments of itch have been slow to emerge, with the majority of focus on antagonism of histamine. Recently, with a new understanding of the pathophysiology of itch transmission, new treatment strategies have been elucidated. Opiate receptor antagonists, antidepressants, antiepileptics, and thalidomide are currently available therapeutic options that have benefited many patients with variegated sources of itch. In addition, research focused on the neuromediators of itch transmission has led to the development of novel targets for itch reduction and great potential for future therapies.

AB - Itch is propagated by complex mechanisms located both peripherally and within the central nervous system. For decades, novel treatments of itch have been slow to emerge, with the majority of focus on antagonism of histamine. Recently, with a new understanding of the pathophysiology of itch transmission, new treatment strategies have been elucidated. Opiate receptor antagonists, antidepressants, antiepileptics, and thalidomide are currently available therapeutic options that have benefited many patients with variegated sources of itch. In addition, research focused on the neuromediators of itch transmission has led to the development of novel targets for itch reduction and great potential for future therapies.

KW - Opioid agonists and antagonists

KW - SSRIs

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=29144450639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144450639&partnerID=8YFLogxK

U2 - 10.1111/j.1529-8019.2005.00035.x

DO - 10.1111/j.1529-8019.2005.00035.x

M3 - Review article

C2 - 16297005

AN - SCOPUS:29144450639

VL - 18

SP - 328

EP - 332

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 4

ER -